PTH and hypoparathyroidism: TransCon PTH (palopegteriparatide) is an investigational prodrug of PTH (1–34), administered once daily, with sustained release of active PTH designed to provide PTH levels in the physiological range for 24 h/day in adults with hypoparathyroidism.